4//SEC Filing
Mirviss Jeffrey B. 4
Accession 0001225208-25-001685
CIK 0000885725other
Filed
Feb 12, 7:00 PM ET
Accepted
Feb 13, 4:32 PM ET
Size
8.6 KB
Accession
0001225208-25-001685
Insider Transaction Report
Form 4
Mirviss Jeffrey B.
SVP&Pres, Periph Intervent
Transactions
- Award
Common Stock
2025-02-11+23,760→ 52,214 total - Tax Payment
Common Stock
2025-02-11$105.98/sh−10,738$1,138,013→ 41,476 total - Sale
Common Stock
2025-02-12$105.06/sh−13,022$1,368,073→ 28,454 total
Footnotes (3)
- [F1]On February 16, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2024 and subject to the completion of the concurrent three-year individual service period. On February 11, 2025, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
- [F2]The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024.
- [F3]Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.787 to $105.26, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Documents
Issuer
BOSTON SCIENTIFIC CORP
CIK 0000885725
Entity typeother
Related Parties
1- filerCIK 0001566094
Filing Metadata
- Form type
- 4
- Filed
- Feb 12, 7:00 PM ET
- Accepted
- Feb 13, 4:32 PM ET
- Size
- 8.6 KB